Inhibitor Therapeutics (INTI) Total Liabilities (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Total Liabilities came in at $3.4 million in Q1 2026, up 8.2% YoY from $3.2 million in Q1 2025, and down 10.29% on a QoQ basis from $3.8 million in Q4 2025.
Inhibitor Therapeutics (INTI) Total Liabilities (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Total Liabilities data on file, last reported at $3.4 million in Q1 2026.
- Quarterly Total Liabilities rose 8.2% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 8.2% YoY) and the FY2025 annual result came in at $3.8 million, up 2.52% from the prior year.
- Total Liabilities declined to $3.4 million in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $4.1 million in Q3 2022 to a low of $3.0 million in Q2 2024.
- A 5-year average of $3.4 million and a median of $3.2 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities increased 12.63% — and 2023, when it declined 22.78%.
- Tracing INTI's Total Liabilities over 5 years: stood at $3.7 million in 2022, then declined by 0.37% to $3.7 million in 2023, then gained by 1.21% to $3.7 million in 2024, then gained by 2.52% to $3.8 million in 2025, then dropped by 10.29% to $3.4 million in 2026.
- The last three Total Liabilities figures came in at $3.4 million (Q1 2026), $3.8 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.41 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Mar 31, 2025 | 3.15 Mn |
| Dec 31, 2024 | 3.71 Mn |
| Sep 30, 2024 | 3.04 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Mar 31, 2024 | 3.16 Mn |
| Dec 31, 2023 | 3.67 Mn |
| Sep 30, 2023 | 3.16 Mn |
| Jun 30, 2023 | 3.04 Mn |
| Mar 31, 2023 | 3.08 Mn |
| Dec 31, 2022 | 3.68 Mn |
| Sep 30, 2022 | 4.09 Mn |
| Jun 30, 2022 | 3.94 Mn |
| Mar 31, 2022 | 3.83 Mn |
| Dec 31, 2021 | 3.68 Mn |
| Sep 30, 2021 | 3.63 Mn |
| Jun 30, 2021 | 3.65 Mn |